|
Video: What is a Stock Split?
|
|
HOOKIPA Pharma is a biopharmaceutical company developing a class of immunotherapeutics based on its proprietary arenavirus platform that is designed to target and amplify a T cell and immune response to disease. Co. is building a proprietary immuno-oncology pipeline by targeting oncoviral cancer antigens, self-antigens and antigens. Co.'s lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papillomavirus 16-positive cancers in a Phase 1/2 clinical trial. Co.'s non-replicating prophylactic Cytomegalovirus vaccine candidate, HB-101, is a potential compound in a Phase 2 clinical trial for kidney transplant patients. According to our HOOKIPA Pharma stock split history records, HOOKIPA Pharma has had 0 splits. | |
|
HOOKIPA Pharma (HOOK) has 0 splits in our HOOKIPA Pharma stock split history database.
Looking at the HOOKIPA Pharma stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into HOOKIPA Pharma shares, starting with a $10,000 purchase of HOOK, presented on a split-history-adjusted basis factoring in the complete HOOKIPA Pharma stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/22/2019 |
|
End date: |
04/23/2024 |
|
Start price/share: |
$14.00 |
|
End price/share: |
$0.77 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-94.54% |
|
Average Annual Total Return: |
-44.03% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$546.64 |
|
Years: |
5.01 |
|
|
|
|
|